Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | CLK2 | P49760 | 2/20 | 0.38 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | FER | P16591 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MARK3 | P27448 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208155 | 0.85 | DYRK1A (0.42) | METAP2NOS1CSNK2A1JAK2PDPK1 | |
| SCHEMBL7579630 | 0.74 | MEN1 (0.44) | CSNK2A1JAK2PDPK1DYRK1ACYP2A6 | |
| SCHEMBL2439787 | 0.69 | ALDH1A1 (0.47) | DYRK1APDGFRBPDGFRACHUKGPR84 | |
| SCHEMBL2980594 | 0.67 | MAPT (0.51) | NOS1LMNAHPGDALDH1A1MAPT | |
| SCHEMBL207738 | 0.65 | AHR (0.42) | METAP2NOS1CSNK2A1JAK2PDPK1 | |
| SCHEMBL14485029 | 0.64 | GPR84 (0.42) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL208062 | 0.64 | MAP2K4 (0.40) | METAP2CDK2AHRCDK5GPR84 | |
| SCHEMBL558182 | 0.64 | NOS1 (0.42) | NOS1PDPK1AHRCYP2A6AXL | |
| SCHEMBL3503303 | 0.63 | AHR (0.35) | METAP2NOS1CSNK2A1JAK2PDPK1 | |
| SCHEMBL1492631 | 0.63 | LMNA (0.41) | METAP2NOS1CSNK2A1JAK2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | claimed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | claimed |
| CN-117440774-A | Biomarkers of age-related macular degeneration | 倍亮生物有限责任公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-114364382-A | Formulations and methods of use of RBP4 inhibitors | 倍亮生物有限责任公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3154974-A1 | TRICYCLIC COMPOUNDS AS ALPHA- 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| WO-2015191401-A1 | TRICYCLIC COMPOUNDS AS ALPHA- 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-17 | — | — | WO | disclosed |
| EP-2431370-B1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-2431370-A1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | METAP2 4459/4885NOS1 151/4885CSNK2A1 4596/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | METAP2 4459/4885NOS1 151/4885CSNK2A1 4596/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | METAP2 4459/4885NOS1 151/4885CSNK2A1 4596/4885 |
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | METAP2 760/4885NOS1 4500/4885CSNK2A1 274/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | METAP2 3907/4885NOS1 287/4885CSNK2A1 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.